DDInter970 DDInter504
Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amitriptyline
Amitriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} (Compound) binds {v} (Gene) CHRM3
CHRM3 {u} (Gene) is bound by {v} (Compound) Desipramine
Ipratropium {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Desipramine
Ipratropium {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amitriptyline
Amitriptyline {u} (Compound) resembles {v} (Compound) Aprindine
Aprindine {u} (Compound) resembles {v} (Compound) Desipramine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Desipramine (Compound)
Ipratropium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Desipramine (Compound)
Ipratropium (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Desipramine (Compound)
Ipratropium (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Triflupromazine (Compound) and Triflupromazine (Compound) resembles Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Aprindine (Compound) and Aprindine (Compound) resembles Desipramine (Compound)